Supernus Pharmaceuticals Inc (SUPN)

Quick ratio

		Dec 31, 2024	Sep 30, 2024	Jun 30, 2024	Mar 31, 2024	Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020
Cash	US$ in thousands	69,331	31,673	52,089	63,401	75,054	94,985	24,706	58,442	93,120	111,492	173,428	115,715	203,434	215,281	223,771	255,642	288,640	204,293	210,975	225,767
Short-term investments	US$ in thousands	384,281	371,537	295,098	234,335	179,820	105,204	126,950	170,126	368,214	280,297	187,359	196,485	136,246	228,571	186,070	135,459	133,893	147,657	163,839	175,104
Receivables	US$ in thousands	142,077	145,408	152,494	147,734	144,155	141,764	136,556	143,568	165,497	164,086	158,063	145,149	148,932	133,676	137,275	127,065	140,877	133,107	126,559	119,195
Total current liabilities	US$ in thousands	292,397	291,508	308,656	314,554	290,196	287,534	252,590	731,545	687,958	725,987	735,536	284,558	315,379	234,711	283,447	240,812	245,108	299,606	269,276	168,335
Quick ratio		2.04	1.88	1.62	1.42	1.38	1.19	1.14	0.51	0.91	0.77	0.71	1.61	1.55	2.46	1.93	2.15	2.30	1.62	1.86	3.09

December 31, 2024 calculation

Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($69,331K + $384,281K + $142,077K) ÷ $292,397K
= 2.04

The quick ratio of Supernus Pharmaceuticals Inc has experienced fluctuations over the past few years. Starting at a healthy level of 3.09 on March 31, 2020, the quick ratio gradually decreased to 0.71 on June 30, 2022, indicating a potential liquidity strain. However, there was a slight recovery to 1.42 on March 31, 2024.

The quick ratio measures the company's ability to meet its short-term obligations with its most liquid assets. A quick ratio above 1 indicates that the company can cover its current liabilities with its quick assets. During the period analyzed, Supernus Pharmaceuticals Inc generally maintained a quick ratio above 1, suggesting a solid liquidity position overall.

It is noteworthy that the quick ratio dipped below 1 during the mid-years of 2022, which may have raised concerns about the company's ability to meet its short-term obligations using its most liquid assets. However, the subsequent improvement in the quick ratio indicates that the company took steps to bolster its liquidity position.

Overall, while the quick ratio of Supernus Pharmaceuticals Inc has shown variability, staying above 1 for most periods indicates the company's ability to meet its short-term obligations with its quick assets, potentially mitigating liquidity risks. Monitoring this ratio can provide insights into the company's short-term liquidity management strategy.